Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

Cardiorentis bags $60M as PhIII nears end; J&J backs HIV player; Novartis nears Horsham sale

Nick Paul Taylor Our top stories in this week's EuroBiotech Report involve the transfer of more than $ 100 million (€92 million) from the wallets of investors to the bank ...

Novartis backs $176M microbiome biotech fund

John Carroll Novartis has stepped in to back Paris-based Seventure Partners' biotech fund focused exclusively on the emerging field of the microbiome as well as nutrition, bringing ...

NICE backs Astellas’ Xtandi in pre-chemo patients, but J&J’s Zytiga isn’t so lucky

Carly Helfand Astellas and Medivation's prostate cancer med Xtandi has been coming up strong behind Zytiga from Johnson & Johnson ever since hitting the market. And now, it's ...

Lilly backs a $25M round for anti-inflammatory startup Symic

Damian Garde San Francisco's Symic raised $ 25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli Lilly to lead ...

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

Novo Nordisk backs out of a diabetes deal with Zosano

Damian Garde Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter ...

FDA panel backs Kythera’s double chin-fighting shot

Damian Garde Kythera won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment. FierceBiotech News

Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes £146M fund

Nick Paul Taylor In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of ...

Astellas backs out of a $760M Alzheimer’s deal with CoMentis

Damian Garde Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $ 760 million. FierceBiotech ...

Baxter backs Rockwell with a $45M hemodialysis deal

Damian Garde Kidney drug developer Rockwell Medical picked up a big co-sign from a leader in the space, signing a deal with Baxter International that will help pay the way for its late-stage ...

U.K. gov names ex-biotech VC as life sci chief, Genfit’s stock jumps, Woodford backs biotechs

Nick Paul Taylor In this week's EuroBiotech Report, the U.K. government underlined the importance it places on life sciences–and the jobs it brings–by creating a position ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS